ClinicalTrials.gg
CompletedNCT06568042Updated Jul 10, 2026

Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

A Phase 2 interventional study of LY3848575 and Placebo in Neuropathic Pain and Distal Sensory Polyneuropathy, sponsored by Eli Lilly and Company. Completed at 76 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
558
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 291 studies in Neuralgia with a site in United States — 50 open to participants now, 61 under way, 5 of them phase 3. Neuralgia · United States.

Enrollment
4th of 261
558 · median 40
Started
2024
with 17 others
Phase 2
78 of 291
5 open now
Registered
258th of 291
by date
Lead sponsor
6 of 291
Eli Lilly and Company

Among the 291 studies in Neuralgia with a site in United States, this one is the 4th largest by enrollment of the 261 interventional ones that give a count, is one of 18 that started in 2024, is one of 78 in phase 2, and was the 258th registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

50 of the 291 studies in Neuralgia with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 291 studies in Neuralgia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee.

Participation may last up to 30 weeks including screening.

03

Conditions studied

  • Neuropathic Pain
  • Distal Sensory Polyneuropathy

Keywords

  • Peripheral Neuropathy
  • Diabetic Peripheral Neuropathy
  • Chemotherapy Induced Peripheral Neuropathy
  • HIV Induced Peripheral Neuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a Visual Analog Scale (VAS) pain value ≥40 and \<95 at screening.
  • Presence of painful distal sensory polyneuropathy (DSP) without prominent motor or autonomic features with gradual or insidious onset with a minimum duration of 6 months and a known cause of nerve injury, such as metabolic, toxic exposure, nutritional, immunologic, infectious, hereditary, multifactorial, or no known cause identified (idiopathic), of symmetrical nature and in lower extremities (with or without involvement of the hands).
  • Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain- relieving therapies and/or nutritional supplements and will not start any new nonpharmacologic pain-relieving therapies and/or nutritional supplements during study participation.
  • Are willing to discontinue all medications taken for chronic pain conditions, except the allowed pain medications.
  • Individuals NOT of may participate in the trial. use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Other etiologies of pain that may not be due to DSP or confound the assessment due to painful DSP.
  • Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest.
  • Have not achieved glycemic control on a stable diabetes treatment regimen for at least 90 days prior to screening, have a healthcare provider who manages the participants' diabetes, and have a (HbA1c) >11% at screening.
  • Cancer within 2 years of baseline, except for:

    • cutaneous basal cell or squamous cell carcinoma resolved by excision, or
    • cancer treatment which led to chemotherapy that caused distal sensory polyneuropathy.
  • Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.
  • Have a surgery planned during the study for any reason.
  • History of chronic alcohol, illicit drug, or narcotic use disorder within 2 years prior to screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
558 participants (actual)

Study arms

  • Experimental
    LY3848575 Dose 1

    LY3848575 low dose administered subcutaneously (SC).

    Drug: LY3848575

  • Experimental
    LY3848575 Dose 2

    LY3848575 mid dose administered SC.

    Drug: LY3848575

  • Experimental
    LY3848575 Dose 3

    LY3848575 high dose administered SC.

    Drug: LY3848575

  • Placebo comparator
    Placebo

    Placebo administered SC.

    Drug: Placebo

Interventions

  • DrugLY3848575

    Administered SC

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS)

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Mean Change from Baseline in Worst Pain Intensity Numeric Rating Scale (WPI-NRS)

    Time frame: Baseline, Week 12

  2. Mean Change from Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Custom Form (CF) v1.1

    Time frame: Baseline, Week 12

  3. Mean Change from Baseline in Pain Interference with Sleep

    Time frame: Baseline, Week 12

  4. Mean Change from Baseline in PROMIS Short Form (SF) Physical Functioning (PF) 10a (PROMIS PF 10a)

    Time frame: Baseline, Week 12

  5. Mean Change from Baseline in PROMIS (SF) Sleep Disturbance 8b (PROMIS SD 8b)

    Time frame: Baseline, Week 12

  6. Mean Change from Baseline in 36-Item Short Form Health Survey Version 2 (SF-36 v2)

    Time frame: Baseline, Week 12

  7. Mean Change from Baseline in Patient's Global Impression (PGI) of Illness Severity as Measured by PGI-Severity

    Time frame: Baseline, Week 12

  8. Mean Overall Improvement as Measured by Patient's Global Impression of Change

    Time frame: Week 12

  9. Use of Rescue Medication

    Time frame: Baseline up to Week 12

  10. Pharmacokinetic (PK): Serum Concentration of LY3848575

    Time frame: Baseline up to Week 12

07

Study locations

76 sites
  • MD First Research - Chandler
    Chandler, Arizona 85286, United States
  • HOPE Research Institute
    Phoenix, Arizona 85032, United States
  • Neuro-Pain Medical Center
    Fresno, California 93710, United States
  • Alpine Clinical Research Center
    Boulder, Colorado 80301, United States
  • Accel Research Sites - St. Pete-Largo Clinical Research Unit
    Largo, Florida 33777, United States
  • Design Neuroscience Center
    Miami Lakes, Florida 33016, United States
  • Conquest Research - Orlando
    Orlando, Florida 32832, United States
  • Charter Research - Lady Lake
    The Villages, Florida 32162, United States
  • Encore Medical Research - Weston
    Weston, Florida 33331, United States
  • Conquest Research
    Winter Park, Florida 32789, United States
  • Integrated Clinical Trial Services, Inc.
    West Des Moines, Iowa 50265, United States
  • Lucida Clinical Trials
    New Bedford, Massachusetts 02740, United States
  • SKY Integrative Medical Center/SKYCRNG
    Ridgeland, Mississippi 39157, United States
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
  • Mid Hudson Medical Research
    New Windsor, New York 12553, United States
  • University of Rochester Medical Center
    Rochester, New York 14618, United States
  • Asheville Neurology Specialists, PA
    Asheville, North Carolina 28806, United States
  • Center for Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Neurology Diagnostics, Inc.
    Dayton, Ohio 45459, United States
  • New Phase Research and Development
    Knoxville, Tennessee 37909, United States
  • Cedar Health Research
    Dallas, Texas 75251, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77043, United States
  • Clinical Trial Network
    Houston, Texas 77074, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Med Trust Research
    Courtice, L1E 2J5, Canada
  • Dawson Clinical Research Inc.
    Guelph, N1H 1B1, Canada
  • Premier Clinical Trial Network
    Hamilton, L8L5G4, Canada
  • OCT Research ULC
    Kelowna, V1Y 1Z9, Canada
  • Genge Partners
    Montreal, H4A 3T2, Canada
  • Richmond Clinical Trials
    Richmond, V6V 2L1, Canada
  • Bluewater Clinical Research Group Inc.
    Sarnia, N7T 4X3, Canada
  • FutureMeds GmbH
    Berlin, 10629, Germany
  • Studienzentrum Dr. Bischof GmbH
    Böblingen, 71034, Germany
  • Universitaetsklinikum Schleswig-Holstein Campus Kiel
    Kiel, 24105, Germany
  • ZNS Siegen
    Siegen, 57076, Germany
  • Studienzentrum Nord-West
    Westerstede, 26655, Germany
  • St. Luke's International Hospital
    Chūōku, 104-8560, Japan
  • Chugoku Central Hospital
    Fukuyama-shi, 720-0001, Japan
  • Mito Medical Center
    Higashiibaraki, 311-3117, Japan
  • Rinku General Medical Center
    Izumisano, 598-8577, Japan
  • Sagara Hospital
    Kagoshima, 892-0833, Japan
  • Kamezawa Clinic
    Kasugai, 486-0817, Japan
  • The Cancer Institute Hospital of JFCR
    Kōtō City, 135-8550, Japan
  • Kikuchi Naika Clinic
    Maebashi, 370-3573, Japan
  • Aizawa Hospital
    Matsumoto, 390-0814, Japan
  • Kojunkai Daido Hospital
    Nagoya, 457-8511, Japan
  • Nishinomiya Municipal Central Hospital
    Nishinomiya, 663-8014, Japan
  • Medical Corporation Sato Medical Clinic
    Ootaku, 143-0015, Japan
  • Minamiosaka Hospital
    Osaka, 559-0012, Japan
  • Fujigaki Clinic
    Ōita, 870-0942, Japan
  • Saga-Ken Medical Centre Koseikan
    Saga, 840-8571, Japan
  • Asama General Hospital
    Saku, 385-0022, Japan
  • Tokyo Shinagawa Hospital
    Shinagawa-ku, 140-8522, Japan
  • Niwa Family Clinic
    Tokyo, 182-0006, Japan
  • Scientia Investigacion Clinica S.C.
    Chihuahua City, 31207, Mexico
  • Investigación Clínica Cuernavaca, S.C.
    Cuernavaca, 62448, Mexico
  • Centro de Investigación Clínica y Medicina Traslacional (CIMeT)
    Guadalajara, 44340, Mexico
  • Health Pharma Querétaro
    Juriquilla, 76230, Mexico
  • Grupo Medico Camino Sc
    Mexico City, 03310, Mexico
  • Medical Care and Research SA de CV
    Mérida, 97070, Mexico
  • Cicmex Centro de Investigación Clínica de México
    Morelia, 58000, Mexico
  • Centro de Investigacion Clinica de Oaxaca
    Oaxaca City, 68020, Mexico
  • Podlaskie Centrum Psychogeriatrii
    Bialystok, 15-756, Poland
  • Centrum Medyczne NEUROMED
    Bydgoszcz, 85-163, Poland
  • Centrum Badan Klinicznych PI-House sp. z o.o.
    Gdansk, 80-546, Poland
  • Neuro-Care Sp. z o.o. sp. kom.
    Katowice, 40-749, Poland
  • Diamond Clinic
    Krakow, 31-559, Poland
  • Santa Familia PTG Lodz
    Lodz, 90-302, Poland
  • Nzoz Neuro-Kard Ilkowski i Partnerzy SPL
    Poznan, 61-853, Poland
  • MICS Centrum Medyczne Warszawa - Chłodna
    Warsaw, 00-872, Poland
  • Chosun University Hospital
    Gwangju, 61453, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Konkuk University Medical Center
    Seoul, 05030, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • The Catholic Univ. of Korea Seoul St. Mary's Hospital
    Seoul, 06591, South Korea
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jan 2026, 16 months.

Of 34 industry-sponsored phase 2 interventional studies under Neuralgia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 22. This study's 16 months is above that.

Counting every sponsor, half of 58 studies reached it within 22 months; a quarter within 11 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 23, 2024
StartActual
Aug 22, 2024
Primary completionActual
Jan 12, 2026
CompletionActual
Apr 15, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06568042
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Aug 22, 2024
Primary completion
Jan 12, 2026
Completion
Apr 15, 2026
Last update
Jul 10, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion